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Renal microvascular assembly and repair: Power and promise of
molecular definition. Developmental assembly of the renal microcircula-
tion is a precise and coordinated process now accessible to experimental
scrutiny. Although definition of the cellular and molecular determinants is
incomplete, recent findings have reframed concepts and questions about
the origins of vascular cells in the glomerulus and the molecules that direct
cell recruitment, specialization and morphogenesis. New findings illustrate
principles that may be applied to defining critical steps in microvascular
repair following glomerular injury. Developmental assembly of endothe-
lial, mesangial and epithelial cells into glomerular capillaries requires that
a coordinated, temporally defined series of steps occur in an anatomically
ordered sequence. Recent evidence shows that both vasculogenic and
angiogenic processes participate. Local signals direct cell migration,
proliferation, differentiation, cell-cell recognition, formation of intercel-
lular connections, and morphogenesis. Growth factor receptor tyrosine
kinases on vascular cells are important mediators of many of these events.
Cultured cell systems have suggested that basic fibroblast growth factor
(bFGF), hepatocyte growth factor (HGF), and vascular endothelial
growth factor (VEGF) promote endothelial cell proliferation, migration
or morphogenesis, while genetic deletion experiments have defined an
important role for PDGF b receptors and platelet-derived growth factor
(PDGF) B in glomerular development. Receptor tyrosine kinases that
convey non-proliferative signals also contribute in kidney and other sites.
The EphB1 receptor, one of a diverse class of Eph receptors implicated in
neural cell targeting, directs renal endothelial migration, cell-cell recog-
nition and assembly, and is expressed with its ligand in developing
glomeruli. Endothelial TIE2 receptors bind angiopoietins (1 and 2), the
products of adjacent supportive cells, to signals direct capillary maturation
in a sequence that defines cooperative roles for cells of different lineages.
Ultimately, definition of the cellular steps and molecular sequence that
direct microvascular cell assembly promises to identify therapeutic targets
for repair and adaptive remodeling of injured glomeruli.
VASCULOGENESIS AND ANGIOGENESIS IN THE
DEVELOPING KIDNEY
The processes that assemble vascular structures during embry-
onic life, whether in the kidney or in other sites, are distinguished
by the presence or absence of contiguous pre-existing vessels and
are termed angiogenesis or vasculogenesis, respectively. Vasculo-
genesis involves the de novo assembly of endothelial progenitor
cells into vessels through migration, proliferation, cell-cell aggre-
gation, assembly and morphogenesis [1–3]. During vertebrate
embryonic development, vasculogenesis begins at gastrulation (at
approximately embryonic day 7, E7, in the mouse). At that time,
extraembryonic mesodermal cells from the posterior primitive
streak migrate into the yolk sac where they aggregate to form
“blood islands.” Mesodermally-derived cells in the blood islands
differentiate into either endothelial progenitor cells, so called
angioblasts, or primitive hematopoietic lineages. The close spatial
and temporal association between the development of these two
cell lineages and their expression of common markers has sug-
gested they have a common precursor, the “hemangioblast” [3].
By E8.5, endothelial progenitor cells from these blood islands fuse
to form a primordial honeycombed vascular network, which
subsequently remodels into a highly vascular plexus that feeds the
developing embryo. Similar vasculogenic steps lead to develop-
ment of the dorsal aorta in the embryo proper [4].
In contrast, angiogenesis involves branching, sprouting and
anastomosis of existing vessels to create new vessels [5]. Prevailing
concepts have asserted that postnatal vascular expansion proceeds
through angiogenic processes. Yet notions about strict segrega-
tion between vasculogenic and angiogenic processes have become
blurred in recent years, particularly in light of better definition
glomerular vascular development [6]. It is now clear that vascu-
logenic processes contribute.
ORIGIN OF GLOMERULAR ENDOTHELIAL CELLS
The metanephric kidney begins to develop around E11.5 in the
mouse. When the ureteric bud invades metanephric blastema, it
branches and mesenchymal cells are induced to convert to an
epithelial phenotype and aggregate in “vesicles” at the tips of the
branches (Fig. 1A). Molecular determinants of this bidirectional
inductive process include c-ret and its ligand, GDNF, a growth
factor originally assigned function in neural development [7, 8].
Formation of a cleft, the so-called vascular cleft, in the comma
and S-shaped epithelial aggregates provides an entry point to
which progenitor endothelial and mesangial cells are recruited
(Fig. 1B) [9]. This site ultimately develops into the vascular pole
of the glomerular capillary tuft. Although little is currently known
about the sequence of events leading glomerular endothelial,
mesangial and epithelial elements to assemble the filtering unit,
remarkable integration is required and several specialized fea-
tures of the glomerular microcirculation are noteworthy. Glomer-
ular endothelial cells develop fenestrae typical of endothelial cells
exposed to vascular endothelial growth factor (VEGF), share a
fused basement membrane with podocytes and are in direct
contact with the mesangial cells that function as pericytes [10, 11].
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Fig. 1. Glomerular microvascular development. (A) Proliferative expansion of this epithelial mass of cells induces vascular endothelial growth factor
(VEGF) expression and increases the population of flk-1 expressing “angioblasts” dispersed in adjacent sites. (B) VEGF, basic FGF and possibly
ephrinB1 direct migration of angioblasts to the developing glomerular vascular cleft. (C) Coordinated recruitment and differentiation of mesangial and
endothelial cells involves paracrine signaling through receptors for platelet-derived growth factor B (PDGF B) and possibly for angiopoietin-1. EphB1
receptors may direct homologous cell-cell recognition required for coordinated endothelial assembly and capillary network formation. VEGF likely
provides ongoing proliferative signals, at least at early steps in the process. (D) Late steps in microvascular maturation involve formation of endothelial
cell-cell junctions, growth arrest, and remodeling of matrix, where a number of cell to cell signaling systems may be invoked, including receptor protein
tyrosine phosphatases (RPTPs) and cadherins.
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Although metanephric organ cultures have provided a rich
source of information about early glomerular epithelial develop-
ment, they previously failed to develop glomerular capillaries as in
vitro tissue culture explants [12, 13]. As a result, considerable
efforts have been applied to defining experimental systems where
determinants of glomerular capillary assembly could be tested.
Early experiments used transplantation of metanephric kidney
from avian and mammalian (rodent) sources to in vivo sites
tractable for experimentation, such as the chick or quail cho-
rioallantoic membrane [14, 15]. Incorporation of vascular cells
from the recipient tissue into glomeruli that developed in the
transplanted tissue led to the conclusion that glomerular capillary
development depended predominantly upon angiogenic pro-
cesses, in which new vessels are recruited to developing glomeruli
from existing vessels in recipient tissue [16]. However, new data
have reconstructed the process of glomerular capillary develop-
ment in the best studied mammals, mice and rats.
Abrahamson and colleagues have defined an important role for
recruitment of relatively undifferentiated mesenchymal cells to
the developing glomerulus from adjacent sites in a vasculogenic
process [6, 17, 18]. When genetically marked embryonic kidneys
were transplanted under the capsule of native adult rodent
kidneys, the transplanted donor tissue was the predominant
source of endothelial cells that populate glomeruli that subse-
quently develop [18]. This result is consistent with their identifi-
cation of endothelial progenitor cells, or angioblasts, that express
VEGF receptor (flk-1) dispersed throughout the donor tissue
[19]. In contrast, recipient-derived endothelial cells incorporated
into glomerular capillaries of transplanted tissue when that em-
bryonic tissue was transplanted into neonatal kidneys. The differ-
ence, depending upon developmental stage of the recipient tissue,
is attributed to the presence of flk-1 (1) angioblasts in the
newborn rodent kidneys [19]. These cells provide a tissue source
of the angioblasts that are recruited to migrate into the vascular
cleft of developing glomeruli and ultimately to assemble into
glomerular capillaries (Fig. 1B). Although loose networks of
endothelial marker positive cells were evident in the donor tissue
[18], substantial evidence supports a role for a vasculogenic
process in glomerular capillary development.
SYSTEMS FOR DEFINING MOLECULAR STEPS IN
GLOMERULAR MICROVASCULAR ASSEMBLY
Developmental studies of gene “knock out” mice have provided
some of the most compelling information about specific roles for
individual receptor tyrosine kinases in the stepwise integration of
endothelial progenitors into mature functional capillaries. Al-
though some striking findings have been defined explicitly in the
glomerular microcirculation, including definition of requirements
for PDGF B/c-sis [20], other data are necessarily derived from
observations of vascular development outside the kidney, since
deficits may compromise embryonic viability prior to renal orga-
nogenesis. Conditional “knock out” technology promises to solve
this problem in the near future, yet each experimental system
imposes its own inherent limitations. Cultured cell systems may
offer important advantages, particularly for defining later steps of
vascular cell assembly and maturation. Due to the remarkable
heterogeneity of vascular endothelium derived from different
tissue sources, more relevant information may be obtained when
the vascular endothelial cells are derived from the kidney and
molecules under scrutiny are expressed in a timely manner in
developing glomeruli.
GENE TARGETING AND SPECIFIC RECEPTOR TYROSINE
KINASES IN VESSEL DEVELOPMENT
At a molecular level, gene “knock out” experiments have
assigned critical roles to a number of specific receptor tyrosine
kinases expressed on endothelial and mesangial cells, including
two of the receptors for VEGF, flt-1 and flk-1 (KDR) [21–23].
Vascular endothelial growth factor (VEGF) is an important
regulator of endothelial cell proliferation and migration [24].
High levels of flk-1 and flt-1 expression are detected at early
developmental stages in endothelial cells. In fact, among those
mesodermal cells that give rise to angioblasts, flk-1 is the first
definitive marker of commitment of endothelial progenitors [25,
26]. Mesodermally-derived angioblasts that express flk-1 are con-
tiguous to endodermal cells that coincidentally express VEGF, at
E7.5, suggesting that VEGF from this source may support differ-
entiation of flk-1 positive cells to endothelial cells [27].
Definitive evidence that flk-1 signaling has a pivotal role in
endothelial differentiation in the mouse embryo comes from
targeted gene disruption studies [28, 29]. Flk-1 deficient mice die
between E8.5 and E9.5, as a result of an early defect in the
development of hematopoietic cells and endothelial cells. Yolk
sac blood islands are absent at 7.5 days and organized blood
vessels are not observed in the embryo at any time.
Despite the overlapping affinities of flk-1 and flt-1 for VEGF,
targeted disruption of flt-1 evokes a different phenotype. In these
animals early endothelial differentiation is not blocked in either
extra-embryonic or embryonic regions, and animals die at later
embryonic stages [30]. The flt-12/2 endothelial cells assemble into
abnormal vascular channels containing aggregates of endothelial
cells within the lumen, suggesting that flt-1 signals endothelial
cell-cell or cell-matrix interactions. Thus, the flt-1 null mice
display disordered organization of the early embryonic vascula-
ture, rather than defects in endothelial differentiation.
Similar findings are seen in animals with VEGF gene inactiva-
tion [31, 32]. Angiogenesis and blood island formation is im-
paired. Notably, loss of a single allele is capable of causing
embryonic lethality at E11 to E12. In aggregate, these genetic
deletion experiments suggest that flk-1 signaling is important in
early steps of endothelial differentiation, and that flk-1 may
interact with ligands other than VEGF to accomplish these steps.
Loss of VEGF or flt-1 function impacts later stages of vessel
development, causing failure of organization and integration.
HOW IS RENAL VASCULOGENESIS INDUCED?
The coordinate expression of VEGF and its receptors during
renal vasculogenesis suggests pivotal function of this ligand/
receptor pair for this process [33, 34]. Two recent reports confirm
important roles for VEGF in developing kidney. Culture of
metanephric kidneys under hypoxic conditions induces VEGF
expression, as well as expression of flt-1, flk-1 on cells that
contribute to developing capillaries [35]. Moreover, neutralizing
antibodies against VEGF block these responses. These findings
suggest that local expansion of cell mass coinciding with cell
division induces VEGF expression [35]. In vivo administration
of VEGF antibodies blocks glomerular and extraglomerular cap-
illary development in newborn mice, consistent with VEGF
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function to recruit and promote proliferation of endothelial cells
[36]. As depicted in Figure 1B, these findings suggest that hypoxia
in the developing glomerular epithelial mass induces VEGF
expression, which, in turn, mediates vasculogenesis through re-
cruitment of the flk-1 expressing angioblasts that reside in mes-
enchymal tissue [19].
ASSEMBLY AND MATURATION OF VASCULAR
STRUCTURES: PDGF B AND RECRUITMENT OF
PERICYTES
Targeted disruption of genes for other growth factors and their
receptors demonstrate that the coordinated recruitment of sup-
portive pericyte-like mesangial cells is critical to the effective
development of glomerular capillaries (Fig. 1C). PDGF-B/c-sis
and PDGFR-b null mice die perinatally from hemorrhage and a
general failure of late stage capillary development [20, 37]. These
animals have fully developed Bowman’s spaces, but the glomeru-
lar capillaries are poorly developed, with a complete absence of
identifiable mesangial cells. Epithelial and endothelial cell types
can be recognized, but their integration into functional capillaries
has been aborted by the apparent failure of glomerular mesangial
recruitment. Outside the kidney, these animals show a remarkable
pattern of intradermal and intracerebral hemorrhage that results
from an apparent failure of capillaries to mature and to recruit
pericytes [20, 38]. Pericytes function in those microcirculations as
mesangial cells do in the glomerulus, to support and contact
endothelial cells. Thus failure to coordinate recruitment of peri-
cyte/mesangial cells with endothelial cells has a profound detri-
mental effect on capillary maturation and integrity.
BASIC FIBROBLAST GROWTH FACTOR, TRANSFORMING
GROWTH FACTOR-b AND HEPATOCYTE GROWTH
FACTOR IN VASCULAR DEVELOPMENT
A number of other growth factors and growth factor receptor
systems have been implicated in angiogenesis and capillary devel-
opment, although the evidence for their participation in the
glomerulus is less direct. The fibroblast growth factors (FGFs) are
among the most potent angiogenic factors known. Mice geneti-
cally deficient in FGF receptors (FGF-R1) show a lethal pheno-
type prior to vascular development and are not useful in studying
kidney development [39]. FGF-R3 knock-out mice reveal abnor-
mal bone development but show no apparent kidney abnormali-
ties [40].
Recent studies, however, suggest that FGFs and their receptors
may participate in renal blood vessel development. Using both
reverse transcriptase-polymerase chain reaction (RT-PCR) and
immunohistochemistry, Ford et al found expression of both
FGF-1 and FGF-2 in cortex and glomeruli of adult rat kidneys
[41]. Although all seven receptor isoforms were expressed in the
cortex, only the IIIc splice variants of each receptor (FGF-R1 to
FGF-R4) were found in glomeruli. Using a similar RT-PCR
strategy, Kee et al identified expression of FGF-R1, FGF-R3 and
FGF-R4 in fetal rat kidneys in late gestation (E21) [42]. FGF-R1
and FGF-R3 protein expression was greater in fetal kidneys than
in kidneys from 12-week-old rats, while FGF-R4 protein was
expressed comparably. Receptor tyrosine phosphorylation pat-
terns leave some doubt as to the developmental roles for FGF in
glomerular development, but the differential expression pattern
suggests specified function for FGF within glomeruli.
Although it is clear that long-term administration of FGF-2 to
rats promoted development of focal segmental sclerosis, with
podocyte foot process effacement and detachment from the
glomerular basal membrane, angiogenic or endothelial prolifera-
tive responses were not identified [43, 44]. Neutralizing antibodies
to bFGF did reduce endothelial proliferative responses during the
recovery phase of the anti-Thy1 mesangiolytic model [45]. In
aggregate, the evidence for FGF and receptor participation in
glomerular vascular development and repair is promising, but
incomplete.
In addition to VEGF and FGF, transforming growth factor
(TGF)-b1 has been assigned important roles in angiogenesis [46].
Exogenously delivered TGF-b1 evokes capillary angiogenesis in
the chick chorioallantoic membrane [47]. During embryogenesis,
TGF-b1 is expressed in many tissues, including endothelial and
hematopoietic precursors [48]. Targeted disruption of the
TGF-b1 gene caused fetal demise around E10.5, accompanied by
defects in the yolk sac vasculature and hematopoiesis [49].
Although initial endothelial differentiation was apparent, num-
bers of flk-1 (1) cells were reduced and assembly of capillary-like
networks was defective. Contacts between endothelial cells either
failed to form or were sufficiently unstable that integrity was
compromised, leading to blood cell leakage into the yolk sac
cavity. Similar findings have been reported in TGF-b receptor
type II deficient mice [50]. In vitro endothelial cell/pericyte
coculture experiments have suggested that TGF-b mediates im-
portant growth inhibitory effects on endothelial cells [51].
Finally, an important role for TGF-b type II receptors in
capillary morphogenesis has been demonstrated by Choi and
Ballerman, in experiments where endogenous receptor function
was abrogated using a dominant negative receptor in transfected
endothelial cells [52]. Both apoptosis and capillary formation were
eliminated by expression of this dominant negative receptor. At
present, it appears that TGF-b may mediate important signals
between pericyte (or mesangial cell) and endothelial cells to
promote and maintain capillary integrity. Undoubtedly, additional
studies will elucidate further roles for TGF-b and its receptors in
regulating glomerular capillary development and repair.
A number of findings suggests that hepatocyte growth factor
(HGF) may participate in glomerular capillary development.
HGF is a potent mitogen and motility factor, acting through its
receptor, the receptor tyrosine kinase, MET [53]. HGF is ex-
pressed in developing human renal cortex [54]. HGF is a potent
angiogenic factor in corneal and in in vitro assays [54]. Cultured
endothelial cells express MET, and HGF has been suggested to
promote angiogenesis through induction of platelet activating
factor (PAF) synthesis, in vivo [55, 56]. Further definition of the
role of HGF and endothelial MET receptors in developing renal
glomeruli is needed. Such studies promise to expand our under-
standing of collaborative interactions between epithelial and
endothelial cell types, particularly if communication parallels that
between hepatocytes and sinusoidal endothelial cells [57].
NEWLY DEFINED RECEPTOR SYSTEMS AND CAPILLARY
ASSEMBLY
TIE2, angiopoietins and capillary maturation
Exciting new information about another family of receptor
tyrosine kinases (RTKs), including TIE1 and TIE2 (Tek) ampli-
fies on this developing theme of coordinated vascular recruitment
Takahashi et al: Renal microvascular assembly and repair 829
and maturation, as depicted in Figure 1, panels C and D [58, 59].
The onset of embryonic expression of receptors TIE1 and TIE2
seems to follow that of flk-1 in endothelial progenitor cells [60].
Two ligands for TIE2 have recently been identified and cloned.
Angiopoietin-1 is a 70 kDa glycoprotein with fibrinogen-like and
a coiled-coil domains [61]. Although angiopoietin-1 binds and
induces tyrosine phosphorylation of TIE2, it does not elicit
proliferation of endothelial cells or their association into tubules
in vitro. However, its high expression in the mesenchyme sur-
rounding developing blood vessels suggests it plays a regulatory
role in the assembly of non-endothelial vessel wall components
[62]. Mice lacking angiopoietin-1 exhibit defects in the remodeling
of their vasculature, with fewer branches and homogeneously
sized vessels. Ultrastructural analysis shows that endothelial cells
are poorly associated with the underlying matrix and do not
properly recruit and associate with periendothelial cells. These
findings contrast with the earlier defects in vasculogenesis dis-
played by VEGF- or VEGF receptor-deficient embryos. Addi-
tional evidence links human families afflicted with hereditary
venous malformations to TIE2 [63]. Two different families show
activating mutations in the tyrosine kinase domain of TIE2 that
are linked with venous malformations. These lesions are charac-
terized by attenuated smooth muscle layer support in conjunction
with the abnormal vascular channels.
A second ligand for TIE2, angiopoietin-2, has been identified
[64]. Although highly homologous to angiopoietin-1, it binds TIE2
and blocks its activation. When overexpressed in transgenic mice,
angiopoietin-2 disrupts blood vessel formation in the mouse
embryo, closely mimicking the phenotype of the angiopoietin-1
knock-out animals [64]. In physiological circumstances of angio-
genesis, angiopoietin-2 is expressed following the angiopoietin-1
expression and only at sites of active vessel remodeling, including
ovary, placenta and uterus. Thus, endothelial TIE2 appears to
communicate critical (yet undetermined) signals for regulating
late vascular development. The ligands TIE2 binds, angiopoi-
etin-1 and -2, appear to accelerate, then retard that function,
respectively, as they are expressed in a temporal sequence in
adjacent supportive cells.
Although explicit roles for TIE2 and angiopoietins in the
glomerulus are not yet defined, the data from both patients with
vascular malformations and mice provide exciting new informa-
tion about the collaboration between cellular elements in devel-
oping and maturing blood vessels [65]. With the excitement comes
a number of new questions about how the paracrine action of
angiopoietins from smooth muscle cells or progenitors may
participate in endothelial recruitment and integration of those
cells. Further studies are needed to evaluate relevance of these
findings to the assembly, remodeling and repair of the renal
glomerular or renal venous circulations.
Endothelial targeting and EPH receptors in angiogenesis
To this point the data reviewed support the hypothesis that the
embryonic glomerular microvasculature develops through se-
quential and cooperative effects of members of the VEGF,
PDGF, TGF-b, FGF, HGF and angiopoietin-1 families. Available
information suggests that PDGF and the angiopoietins (1 and 2)
participate in the recruitment of pericytes cells to their endothe-
lial partners. Is there an analogous receptor-ligand system that
mediates (homologous) cell-cell recognition and targeting be-
tween differentiated endothelial cells, permitting them to find the
right partner to integrate into capillary networks?
After a primary capillary plexus is formed, endothelial cells
extend filopodia and sprout from the plexus in an angiogenic
process to develop a mature vascular plexus [66]. The success of
this vascular network integration requires that endothelial pro-
genitor cells discriminate the paths they migrate, and the cells they
contact in order to develop the highly organized and reproducibly
assembled vascular architecture. In no other organ is this archi-
tectural assembly more critical than in the kidney, where the
filtration apparatus and countercurrent processes require intimate
integration between epithelial and vascular structures.
Remarkable similarities exist between the developmental tar-
geting problems confronting axons and those of endothelial cells
in the developing vasculature. Axons migrate in highly reproduc-
ible patterns toward either neural or muscle cell targets, based on
local molecular guidance signals [67]. Despite the great distances
axons migrate, they make very few errors of navigation, thanks to
remarkably specific guidance cues presented by cells in their
environment. Recent evidence suggests similarities in targeting
processes are also shared between vascular and neural networks at
the molecular level, particularly among receptor tyrosine kinases
of the Eph family.
Eph receptors currently comprise a family of at least 13
individual members that are expressed in species from Xenopus
laevis to Homo sapiens in a highly tissue-restricted distribution
[68]. Recent changes in the nomenclature have segregated ligands
(ephrins) and receptors (Ephs) into two distinct classes based on
the structural characteristics of the ephrins [69]. Ligands of the
ephrinA series are glycosylphosphatidylinositol linked, while those
of the ephrinB series are transmembrane proteins. EphA recep-
tors display overlapping affinities for ephrinA series ligands, and
the same relationships hold for EphB subclass receptors. Recip-
rocal compartmentation of ligands with their receptors has been
noted during embryonic development, suggesting important roles
for these molecules in defining the developmental organizational
plan [70].
Interactions between cells displaying ligands and receptors of
these families direct cell aggregation and targeting behavior, as
well as other organizational responses [68]. The targeting func-
tions of these molecules may be best illustrated in the developing
retinotectal system where retinal axons expressing EphA3 recep-
tors migrate through tectal fields of cells displaying a gradient of
the ligand ephrinA2. These axonal projections select their final
destinations based on local levels of ligand expression [71].
In the vascular system, recent evidence implicates the Eph
family receptor, EphA2 (Eck), in angiogenic and chemotactic
responses [72]. Endothelial expression of the EphA2 ligand,
ephrinA1 (B-61/Lerk-1), is induced by TNFa, and ephrinA1
antibodies block angiogenic responses to TNFa in the rabbit
corneal angiogenesis assay. Our lab recently identified expression
of a second Eph family receptor, EphB1 (ELK), in human renal
microvascular endothelial cells (HRMEC) and in glomerular
endothelial cells in situ [73]. In collaboration with the Abraham-
son lab, we identified high level expression of both EphB1
(receptor) and ephrinB1 (ligand) in developing and mature
murine glomeruli. Mesenchymal cells in the subcapsular cortex
displayed intense EphB1 and ephrinB1 staining in a pattern
similar to that of flk-1. EphB1 staining was seen in developing
glomeruli, as was ephrin-B1 immunoreactivity. In contrast to the
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developing kidney, mesenchymal and interstitial cells no longer
expressed EphB1, ephrinB1, or flk-1 in the adult mouse kidney,
while EphB1 and ephrin-B1 expression persisted on arteriolar
intimal cells and glomerular capillary endothelial cells.
In vitro studies showed ephrinB1 is capable of inducing cultured
human renal microvascular endothelial cells to assemble into
capillary-like structures, while ephrinA1 did not [73]. Recent
evidence supports an important role for juxtacrine (cell to cell)
EphB1/ephrin-B1 interactions in signaling recognition steps re-
quired for endothelial commitment to capillary-like morphogen-
esis. Interruption of this interaction blocks capillary-like assembly
[92]. Our findings provide early evidence that Eph/ephrin inter-
actions may participate in the cell-cell recognition processes
required for glomerular capillary assembly. Indeed, we speculate
that targeting functions analogous to retinotectal neural targeting
may direct endothelial progenitors to the vascular cleft during
glomerular development.
Receptor tyrosine phosphatases and vascular assembly:
Predictions
Although sufficient data are not yet in place to assign important
functions to yet another class of cell surface receptors, several
independent lines of evidence suggest that receptor protein
tyrosine phosphatases (RPTPs) may participate importantly in
late stages of capillary development (Fig. 1D). If the analogies
between guidance systems that direct neuronal network and
vascular network assembly hold (Table 1), strong evidence for
RPTP function in axonal guidance may be relevant [74]. A
particularly critical late step in both developmental and reparative
capillary development is the arrest of endothelial cell proliferation
(Fig. 1D).
Several studies point to RPTPs as possible molecular transduc-
ers of growth arrest signals. Sodium orthovanadate, the potent
protein tyrosine phosphatase (PTP) inhibitor, releases density
arrest and stimulates capillary morphogenesis in confluent endo-
thelial cells [75–77]. PTP activity is markedly increased in cultured
nonendothelial cells at high density where growth arrest is seen
[78, 79]. Finally, a Type III RPTP, DEP-1 (or ECRTP/HPTPh)
[80–82] is expressed in human renal microvascular endothelial
cells and in glomerular endothelial cells, in situ [83; T.Takahashi
and T.O. Daniel, unpublished results]. The Type III family
includes the glomerular epithelial phosphatase, GLEPP1 [84], as
well as two Drosophila RPTPs, DPTP10D and DPTP99A [85]
that participate in neural targeting [74]. DEP-1 is prominently
expressed in vascular sites, including glomerular endothelial cells,
and in some renal epithelial cells [83]. Its expression is reduced in
migrating and proliferating endothelial cells [83]. Indeed, cultured
cell studies of human renal microvascular endothelial cells sup-
port a role for DEP-1 to sense and transduce signals that may
mediate growth arrest [93]. This and other RPTPs may be
required to arrest proliferation and migration of endothelial cells
during developmental capillary maturation and upon repair fol-
lowing injury.
Glomerular capillary repair
The findings summarized above have identified molecular
determinants that contribute to developmental glomerular capil-
lary assembly. A major motivation for this work remains the
expectation that, at least at some level, repair recapitulates
development. We anticipate that successful repair follows sequen-
tial steps represented in the left panel of Figure 2. Derangement
of that process may lead to the sclerotic outcome seen in the right
panel. Where are the developmental studies applicable to further
definition of glomerular and other microvascular renal repair
processes?
In several reversible glomerular injury models, many of the
endothelial cells display proliferative responses and several mor-
phological features of angiogenesis [45, 86–88]. Johnson and
colleagues have shown that brisk endothelial proliferation accom-
panies glomerular repair following acute injury in the mesangio-
lytic anti-Thy-1 model [45]. In this experimental system, mesan-
giolysis leads to ballooning and distention of capillary endothelial
cells as they lose their support from adjacent mesangial cells. The
number of proliferating endothelial cells in a glomerulus is
increased seven- to ninefold during days 2 to 7 following the
mesangiolytic injury [45]. Consistent with the increased local
Table 1. Neural and microvascular networks share remarkable similarities
Neural network Vascular network
Basic mechanisms 1 trillion neurons .1 trillion endothelial cells
3 growth cones 3 filopodial extension
3 neurite extension 3 capillary tube formation
Involved processes —Attachment During development only During development and repair
—Migration
—Cell-cell connection
—heterologous
—homologous
Key molecules —Cell adhesion molecules —Ig-CAM —PECAM
—Cadherin —VE cadherin
—Receptor tyrosine —FGF receptor —PDGF receptor
kinases (RTK) —Trk receptor —VEGF receptor
—Eph receptor —Eph receptor
—Receptor protein tyrosine —RPTP B —DEP-1 (?)
phosphatases (RPTP)
—Matrix proteins —Fibronectin —Fibronectin
—Laminin —Laminin
—Others —Netrins
—Semaphorins
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production of VEGF and bFGF following such an injury, neutral-
izing antibodies against VEGF and bFGF, but not PDGF, re-
duced endothelial proliferation. However, the outcome of reduc-
ing endothelial proliferation upon capillary repair is not yet fully
investigated. Other data suggest that repair recapitulates devel-
opment. In a second model of glomerular injury, the Habu snake
venom model, endothelial repair involves migration and elonga-
tion of endothelial cell processes from the vascular pole, much as
was described above for the developmental steps in glomerulo-
genesis [87]. It is not yet clear whether this represents recruitment
of endothelial replacement cells from a local repository, or from
extraglomerular sites.
It is now obvious that glomerular cell proliferation is only one
part of the repair process. A number of questions seem important
in light of the developmental findings. Are angioblasts recruited to
repair sites from repositories either within or outside the glomer-
ulus? Are all glomerular endothelial cells equally competent to
proliferate, migrate and integrate into repairing capillaries? How
are proliferation of endothelial and mesangial cells coupled to
their structural integration into capillaries under repair?
Some provocative results may be pertinent to these questions.
We have identified small subpopulations of endothelial cells
expressing the PEC-1 antigen in normal human glomeruli [89].
Among cultured human renal microvascular endothelial cells,
those expressing this antigen display capacity to assemble into
capillary-like structures in vitro. We speculate that these rare
PEC-1 (1) glomerular cells may serve as a local repository of
proliferation competent endothelial progenitors capable of repop-
ulating capillaries following damage.
As is depicted in Figure 2, success (left panels) or failure (right
panels) of many of the developmental steps outlined above likely
determines whether normal function is repaired following renal
injury. Certainly the success of the repair process in any capillary
bed, including the glomerulus, requires not only proliferation of
endothelial and mesangial cells, but also their reintegration into
functional capillary structures.
THE FUTURE
The potential for therapeutic strategies to exploit fundamental
properties of the microcirculation is great. The microvasculature,
in kidney as in other organs, is a dynamic organ that retains
developmental potential throughout life. It is the functional
gatekeeper directing flow of inflammatory cells to tissue sites of
injury. It actively regulates thrombosis and fibrinolysis. It supports
growth and metastasis of solid tumor neoplasms. Its tissue specific
heterogeneity fundamentally defines function of organs such as
kidney and intestine, and is critical in the central nervous system.
It is a major conduit for drug delivery to tissue sites. We anticipate
that future gene-based and cell-based therapies are likely to target
the microvasculature, expanding considerably on approaches to
glomerular disease, cancer, and vascular diseases, as well as
chronic inflammatory conditions.
Early experiments have proved conceptually that mesangial
cells may be delivered to the glomerular microcirculation and
incorporated into viable structures there [90]. Recent evidence
shows that endothelial cell precursors can be purified from
circulating blood, cultured and returned to the circulation where
they incorporate into capillaries that regenerate at sites of skeletal
muscle ischemia [91]. These findings suggest the possibility of
coupling gene replacement technologies with targeted cell re-
placement approaches, to deliver genetically modified endothelial
cells to tissue sites where they may incorporate into microvascular
beds. Once incorporated, such modified endothelial cells could
potentially deliver biological products capable of ameliorating or
modifying primary disease processes. If cultured “angioblasts” can
be isolated from the circulation in sufficient numbers, cultured
Fig. 2. Alternative post-injury responses.
Capillary reassembly into new microvascular
networks leads, under optimal circumstances, to
remodeling and repair of the glomerulus
through processes shown on the left.
Alternatively, disordered repair or remodeling
may contribute to the destructive processes
depicted on the right, ultimately resulting in
glomerulosclerosis.
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and amplified, transfected and selected for exogenous gene
production, then finally delivered back into the circulation for
integration into selected sites, innumerable therapeutic strategies
may develop. Whether or not these approaches ultimately yield
tractable therapeutic strategies, their development will provide
fertile ground for identifying molecular and cellular processes in
experimental systems.
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APPENDIX
Abbreviations used in this article are: bFGF, basic fibroblast growth
factor; E number, embryonic day; Eck, Eph family of tyrosine receptors,
EphA2; ELK, Eph family receptor, EphB1; Eph, family of tyrosine
kinases; ephrins, ligands of Eph receptors; FGF, fibroblast growth factor;
flk-1, vascular endothelial growth factor receptor; HGF, hepatocyte
growth factor; HRMEC, human renal microvascular endothelial cells;
MET, receptor tyrosine kinase of hepatocyte growth factor; PAF, platelet
activating factor; PDGF, platelet-derived growth factor; PTP, protein
tyrosine phosphatase; RPTP, receptor protein tyrosine phosphatase;
RTK, receptor tyrosine kinase; RT-PCR, reverse transcriptase-polymer-
ase chain reaction; TGF-B, transforming growth factor-beta; VEGF,
vascular endothelial growth factor.
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